TERN-701 CARDINAL Trial December 2025 Data Update DECEMBER 8, 2025 | NASDAQ: TERN Forward-looking Statements and Disclaimers This presentation contains forward-looking statements about Terns Pharmaceuticals, Inc. (the "Company," "we," "us," or "our") and its industry within the meaning of the federal securities laws that involve substantial risks and uncertainties. Forward-looking statements include statements related to or in connection with expectations, timing and potential results of clinical trials and ...

VIEW SHARE Netflix and Warner Bros. combined will have 9.2% TV viewshare in the U.S. Nielsen Share of U.S. TV Time By Distributor 1 October 2025 October 2025 Pro Forma YouTube The Walt Disney Company Netflix & Warner Bros. NBCUniversal FOX Paramount Discovery Global 12.9% 11.4% 9.2% 8.6% 4.4% 8.4% 8.2% 1.2% HBO / HBO Max YouTube 12.9% The Walt Disney Company NBCUniversal FOX Paramount Netflix 11.4% 8.6% 8.4% 8.0% 5.6% 8.2% Warner Bros. Discovery 1.2% HBO / HBO Max ...

NYSE-A:CTGO TSX-V:DV | NYSE-A:DVS MERGER TO CREATE A NEW NORTH AMERICAN HIGH-GRADE, MID-TIER SILVER & GOLD PRODUCER AND DEVELOPER I N V E S T O R P R E S E N TAT I O N D E C E M B E R 2 0 2 5 W W W . C O N T A N G O O R E . C O M W W W . D O L L Y V A R D E N S I L V E R . C O M DISCLAIMER LEGAL DISCLAIMER The information contained in this presentation furnished by or on behalf of Dolly Varden Silver Corporation ("Dolly Varden") or Contango ORE, Inc. ("Contango") has been prepared in respect of the proposed ...

ASH 2025 ANALYST AND INVESTOR EVENT Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer December 8, 2025 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, expectations regarding the combinability and therapeutic potential of ziftomenib with other th ...

Paramount's $30 all-cash offer provides greater value and certainty to WBD shareholders December 8, 2025 Disclaimer This presentation is provided for informational purposes only and for no other purpose. Certain information contained herein has been obtained from published sources prepared by third parties that Paramount Skydance Corporation ("Paramount") believes to be reliable. Moreover, certain information in this presentation is based on assumptions, estimates and other factors that were available to Pa ...

Home BancShares Announces Acquisition of Mountain Commerce Bancorp, Inc. FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements which include, but are not limited to, statements, estimates and projections about the benefits of the business combination transaction involving Home BancShares, Inc. ("HOMB") and Mountain Commerce Bancorp, Inc. ("MCBI"), including the combined company's future financial condition, operating results, plans, expectations, goals and outlook for the future. ...

Financial Status & Milestones - Theravance Biopharma had approximately $333 million in cash with no debt and expects to remain at similar levels in Q4 2025 [7] - The company anticipates $175 million in near-term milestones based on TRELEGY and YUPELRI sales [7] - Theravance Biopharma has a 35% U S profit share with Viatris for YUPELRI, with IP protection into 2039 [7] Ampreloxetine & CYPRESS Trial - Ampreloxetine targets approximately 40,000 underserved patients in the U S with symptomatic nOH due to MSA [7] - The Phase 3 CYPRESS trial completed enrollment in Q3 2025, with topline data expected in Q1 2026 [7] - In a REDWOOD pre-specified MSA subgroup analysis (n=40), the greatest difference was observed in the 6-item OHSA composite score [48, 51] - Approximately 70-80% of patients with MSA will develop nOH in their lifetime, and despite treatment with available pressor agents, 68% remain symptomatic [30] Commercial Opportunity - The U S market includes approximately 40,000 MSA patients with nOH [7, 83, 96] - Only approximately 34% of patients are currently treated, indicating a significant unmet need [84] - The average launch price for chronic neurology therapies is approximately $333,000 [111]

Transformational Utica Shale Acquisition Infinity Acquires Antero's Ohio Assets December 2025 Transformational Acquisition in Core of Utica Shale Transformational Acquisition in Ohio Utica Shale • Highly contiguous acreage improves long lateral well development and adds high quality inventory across all phase windows, improving overall break-evens CAPTURES VERTICAL INTEGRATION BENEFITS THROUGH ACQUIRED MIDSTREAM ASSETS INR to acquire undivided 51% interest of a high growth, high-return acquisition adjacent ...

Aura Day 2025 D E C E M B E R 2 0 2 5 To find, mine and provide the most important and essential ores that allow the world and mankind to create, innovate and prosper. Aura Day team Seasoned Management Team Glauber Luvizotto Isabela Dumont Head People, Communications & Sustainability Natasha Utescher Head of IR and Treasury Frederico Silva Director of Operations Aura Borborema, Brazil Francisco do Carmo Director of Operations Aura Minosa, Honduras Pitágoras Costa Director of Projects and Construction Richar ...

Antero Resources (NYSE: AR) Legal Disclaimer This presentation includes "forward-looking statements." Such forward-looking statements are subject to a number of risks and uncertainties, many of which are not under AR's control. All statements, except for statements of historical fact, made in this presentation regarding activities, events or developments AR expects, believes or anticipates will or may occur in the future, such as those regarding our financial strategy, future operating results, financial po ...